Should You Buy Pfizer Stock For Its Cash?
Today’s big story: Could Nvidia Stock Fall 50%? Follow The Cash
Pfizer (PFE) generated free cash flow equal to 7.2% of its market value over the last twelve months. That compares with 4.3% for the median S&P 500 company. A yield that high usually signals one of two things: a business on sale, or a business the market expects to shrink. So how solid is the cash Pfizer is producing?

Pfizer’s Free Cash Flow Has Held Up And Grown
On the record so far, it is solid. Pfizer’s free cash flow was $11.8 billion over the twelve months to September 2026, up from $10.4 billion a year earlier. Two years earlier, in the twelve months to September 2024, it was $8.23 billion, and measured over twelve months at every quarter end since October 2023, it has never dropped below zero. Its low in that stretch was $4.79 billion, in the twelve months to December 2023.
That cash matters to a shareholder whether or not Pfizer hands it out. An owner holds a claim on the free cash a company generates, just as on its profit. When investors come to value that cash, the share price tends to follow, more so when the cash keeps rising.
Pfizer generates its cash by selling medicines at wide margins. Its operating margin was 26.1% over the last twelve months, compared with 18.9% for the S&P 500. Capital spending took only 16.8% of the cash its operations brought in.
Pfizer also carries debt. Pfizer’s net debt, total debt minus cash and short-term investments, was $48.4 billion at the end of September, equal to 29.4% of its market value. Counting that debt, free cash flow comes to 5.5% of Pfizer’s enterprise value, its market value plus net debt. Operating income covered interest expense 6.1 times over the last twelve months.
Pfizer Faces Lost Exclusivity On Key Drugs
A yield this high can mean the market doubts this cash will keep growing, and management has flagged one reason for caution. On the November 3 call, management listed the loss of exclusivity for Ibrance and Xtandi in the U.S., and for Eliquis internationally at the end of 2026, among the forces it sees in 2027.
Growth is already slow. Pfizer’s revenue rose 1.3% over the last twelve months, a slower pace than each of five large peers. The closest of them, Bristol Myers Squibb, grew 4.2%. Management’s stated objective is returning to growth toward the end of the decade. Before then, it expects headwinds from lost exclusivity over the next several years.
Management is working to replace the sales at risk. Newly launched and acquired products brought in $3.8 billion in the third quarter, growing 32% on management’s operational measure. Management also expects to deliver nearly all of $7.2 billion in net cost savings by the end of 2026, and plans another $2.5 billion from 2027 through 2029.
Pfizer has not yet given a forecast that covers those losses. On November 3, it raised its 2026 revenue guidance to $63 billion at the midpoint, from $61.5 billion. On the results so far, Pfizer looks more like a business on sale than one in decline; the doubt is about the years after 2026.
When Pfizer Will Next Report Its Cash And Debt
Management will give its 2027 guidance around the middle of December. Pfizer is expected to report its next quarterly results in February 2027. An owner still needs to know whether free cash flow keeps rising once the exclusivity losses arrive, and whether Pfizer can carry its debt through them.
Turning to debt, management put its leverage ratio at 2.6 times at the end of the third quarter. That sat slightly below its 2026 target of 2.7 times. It expects leverage to stay around current levels, or move modestly higher, while the exclusivity losses play out. Twelve-month free cash flow and that leverage ratio are the measures to watch in the February report.
Pfizer’s cash is real, but so is the risk tied to a handful of drugs. An owner of a single stock bears all of it. Spreading income across many cash-rich businesses can keep it coming with smaller drops when one of them stumbles.
More Income. Smaller Drops.
Is your portfolio paying you enough? The Trefis Income Solution holds 50 dividend stocks yielding about 3x the S&P 500, each with at least 10 straight years of dividends. In backtests, it lost less than the S&P 500 in all 9 big selloffs since 2018. Why not choose a better approach?
Spot an error or want more like this? Tell us in 10 seconds.